Fig. 4From: Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 monthsSeverity of MS relapses that occurred in the efficacy set (A) and completed set (B), by visit Data presented as percentage of patients (Wilson 95% CI) CI, confidence interval; M, Month; MS, multiple sclerosisBack to article page